'对患者来说,这确实是艰难时刻':Biohaven首席执行官称FDA繁文缛节阻碍罕见病治疗药物获取
'It's really a dire time for patients': Biohaven CEO says FDA red tape is blocking access to rare disease treatments
生物技术与制药领域的最新动态
'It's really a dire time for patients': Biohaven CEO says FDA red tape is blocking access to rare disease treatments
FDA rejects Disc's rare disease drug despite commissioner's voucher
Illumina completes acquisition of SomaLogic from Standard BioTools - BizWest
Expert Outlook: 10x Genomics Through The Eyes Of 10 Analysts - Benzinga
With the FDA's Moderna decision, vaccine makers face increasingly uncertain regulatory environment
FDA clears Encora Therapeutics’ wearable wrist device for essential tremor
What were the biggest clinical trial flops of 2025?
After R&D head exits, Immunocore CEO pairs ambition with caution for growing cancer portfolio
BofA Maintains Hold Rating on Agilent Technologies (A) After Q2 Report - MSN
Gilead gets cancer drug from China-based Genhouse for $80M upfront
Pentagon adds, then withdraws, WuXi AppTec to Chinese military list
Vertex’s CRISPR therapy rebounds in latest earnings
Why Is 10x Genomics (TXG) Stock Soaring Today - Finviz
Lilly appeals retatrutide classification ruling in case that could impact compounders
Holiday notice
In the clinic for Feb. 13, 2026
Other news to note for Feb. 13, 2026
Regulatory actions for Feb. 13, 2026
Money raised by biopharma
Biopharma money raised: Jan. 1-Feb. 12, 2026